Biogen has announced new Phase 3 data showing that, after nearly 2.5 years of treatment, Aduhelm continued to reduce two key Alzheimer’s disease pathologies.
Sanofi and Blackstone today announced a strategic, risk-sharing collaboration under which funds managed by Blackstone Life Sciences will contribute up to €300m ($329m) to accelerate development for subcutaneous formulation and delivery of anti-CD38 antibody...
Novo Nordisk is expanding its existing collaborative research partnership in oral drug delivery technologies with the Massachusetts Institute of Technology (MIT) and Brigham and Women’s Hospital (BWH).
Stevenage Bioscience Catalyst (SBC) has launched an accelerator program for biotech start-ups focusing on data-enabled drug discovery, genomics and advanced therapies: aiming to give such companies the skills they need to get potential new drugs and therapies...
The authors of clinical data published in Nature Medicine this week said the findings indicate the use of a live biotherapeutic (LBP) with immunotherapy medicine can improve survival in patients with metastatic kidney cancer.
Alexion, AstraZeneca’s Rare Disease group, has closed an exclusive global collaboration and licence agreement with Neurimmune AG for NI006, an investigational human monoclonal antibody for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).
Releasing data from both Phase 3 and booster trials, Sanofi and GSK have announced they will submit the results as the basis for regulatory applications for their COVID-19 vaccine.
Moderna has initiated the Phase 3 portion of its pivotal respiratory syncytial virus (RSV) vaccine trial: looking towards its ultimate goal to combine the vaccine with its COVID-19 and flu boosters into a single dose booster.
PerkinElmer’s Sirion Biotech business is teaming up with the Centre for Genomic Regulation (CGR) to jointly develop new generation adeno-associated virus (AAV) vectors for type 1 and type 2 diabetes gene therapy in the pancreas.
Moderna is expanding its mRNA pipeline with three new development programs: with vaccine candidates against herpes simplex virus (HSV), varicella-zoster virus (VSV) and a new checkpoint cancer vaccine.
A number of intranasal vaccines against COVID-19 are in development: hoping to provide a point of difference against authorized vaccines but also create a springboard for wider development against other respiratory diseases.
Lipid nanoparticle systems (LNPs) as a delivery mechanism for novel drug modalities are proving effective, but there are bioanalytical challenges associated with encapsulation, says an expert.
AffaMed Therapeutics has announced that the US FDA has cleared its Investigational New Drug (IND) application for the clinical development of AM712 (ASKG712), a novel proprietary bispecific biologic molecule blocking both vascular endothelial growth factor...
IASO Biotherapeutics and Innovent Biologics have announced that the FDA has granted Orphan Drug Designation (ODD) to their fully human anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed and/or...
Seismic Therapeutic, Inc., a biotechnology company advancing machine learning for immunology drug development, has announced its launch and $101m in Series A financing.
Fujifilm Corporation has launched a new global life sciences strategic investment fund: starting off with 7B¥ ($60m) targeting early-stage biotech companies.
Having built up its mRNA expertise with its COVID-19 vaccine, Pfizer now sets out its strategy for the future. “Going forward, we plan to continue to capitalize on the leadership we have built in both mRNA R&D and manufacturing."
Mission Bio says it is paving the way for the routine use of its technology in clinical trials on materials to support the next wave of life-saving CGT treatments.
Valneva and Pfizer have reported further positive Phase 2 data for their Lyme disease vaccine candidate, VLA15, with a Phase 3 trial set to start in Q3, 2022.
The Coalition for Epidemic Preparedness Innovations (CEPI) has launched a Call for Proposals to improve the thermostability of vaccines: with a particular interest in temperature-stable vaccine nasal sprays, microarray patches, or orally administered...
Biogen has exercised its option to participate in the development and commercialization of mosunetuzumab, an investigational T-cell engaging biospecific antibody targeting CD20 and CD3 in development for B-cell non-Hodgkin’s lymphoma and other therapeutic...
Biogen releases further details on how its Phase 4 post-marketing confirmatory study for Alzheimer’s drug, Aduhelm, will run: including increased enrolment and enhanced efforts to encourage diversity.
Netherlands-based gene therapy company, VectorY Therapeutics, and Wageningen University have signed a strategic collaboration agreement for the development of novel baculovirus-based AAV production technologies.
Biotech EdiGene has announced an R&D collaboration with Haihe Laboratory of Cell Ecosystem to develop hematopoietic stem cell regenerative therapies and platform technology.
Pfizer and BioNTech expect to produce four billion doses of their COVID-19 vaccine in 2022: regardless of whether the current vaccine or a new Omicron specific vaccine is needed.
Charles River and La Jolla Institute for Immunology (LJI) are collaborating on a new project to uncover how different cells in the human immune system respond to SARS-CoV-2 in early, acute infection.
Vir Biotechnology and the Bill & Melinda Gates Foundation have partnered up to develop broadly neutralizing antibodies designed to provide a ‘vaccinal effect’ for the treatment of HIV and prevention of malaria.
While the last two years have seen the successful development of COVID-19 vaccines, the emergence of variants highlights the speed at which the pandemic - or indeed any other virus threat - can evolve. As a result, development of novel vaccine candidates...
BioNTech and Crescendo, a clinical stage immuno-oncology company developing targeted T cell enhancing therapeutics, have entered a multi-target discovery collaboration to develop novel immunotherapies for cancer and other diseases.
Alexion, AstraZeneca’s Rare Disease group, has entered into an exclusive global collaboration and licence agreement with Neurimmune AG for NI006, an investigational human monoclonal antibody currently in Phase Ib development for the treatment of transthyretin...
Bayer AG and Mammoth Biosciences, Inc., have announced a strategic collaboration and option agreement for the use of Mammoth’s CRISPR systems to develop in vivo gene-editing therapies.
Clover Biopharmaceuticals, a clinical-stage biotech developing novel vaccines and biologic therapeutic candidates, has started construction on a new R&D Center in Zhangjiang Biotech and Pharmaceutical Industrial Base in Shanghai.
Pfizer and BioNTech, in what will be the third mRNA vaccine collaboration between the two companies, are teaming up on the development of a vaccine for the prevention of shingles.
Biopharmaceutical company ImmixBio has been granted Rare Pediatric Disease (RPD) designation from the US Food and Drug Administration (FDA) for IMX-110 for the treatment of a life-threatening form of pediatric cancer in children, rhabdomyosarcoma.
Evotec SE has received a €7.5m ($8.5m) grant from the German Federal Ministry of Education and Research (BMBF) for the development of EVT075, a potential immunomodulatory therapy against COVID-19.
A booster shot of Moderna’s COVID-19 vaccine increases neutralizing antibody levels against Omicron approximately 37-fold compared to pre-boost levels, according to data released by the company today.
A single booster dose of Sanofi and GSK’s recombinant adjuvanted COVID-19 vaccine candidate delivered ‘consistently strong immune responses’, according to data released by the companies.
Novartis has introduced its T-Charge platform at ASH 2021, which it says will serve as the foundation for various new investigational CAR-T cell therapies in its pipeline.
Oxford Biomedica plc has announced an extended commercial supply agreement with Novartis for the manufacture of lentiviral vectors for several Novartis CAR-T products.
Memo Therapeutics AG will receive CHF 10.5m (US $11.4m) from the Swiss government to clinically develop a SARS-CoV-2 antibody against COVID-19, allowing it to start Phase 1 studies in Q1, 2022.
